0001562180-22-006580.txt : 20220909
0001562180-22-006580.hdr.sgml : 20220909
20220909160927
ACCESSION NUMBER: 0001562180-22-006580
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211101
FILED AS OF DATE: 20220909
DATE AS OF CHANGE: 20220909
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duker Jay S.
CENTRAL INDEX KEY: 0001630864
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 221236303
MAIL ADDRESS:
STREET 1: C/O ELEVEN BIOTHERAPEUTICS
STREET 2: 215 1ST ST. #400
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4/A
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4/A
2021-11-01
2021-11-03
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001630864
Duker Jay S.
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
false
true
false
false
Chief Operating Officer
Stock Option (Right to Buy)
11.47
2021-11-01
4
A
false
239700.00
0.00
A
2031-11-01
Common Stock
239700.00
239700.00
D
The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months.
Due to an administrative error, the Reporting Person's previous Form 4 filed on November 3, 2021 incorrectly reported the Reporting Person receiving an option grant of 305,000 shares of common stock when it should have been reported as 239,700 shares of common stock.
/s/ Ron Honig, Attorney-in-Fact
2022-09-09